Patents Represented by Attorney David E. Boone

Find this attorney in the Justia Lawyer Directory

  • Heterocyclic compounds and their preparation and use
    Patent number: 5821371
    Abstract: The present invention relates to therapeutically active azacyclic or azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 13, 1998
    Assignee: Eli Lilly and Comany
    Inventors: Charles A. Alt, Leander Merritt, Gary A. Rhodes, Roger L. Robey, Eldon E. Van Meter, John S. Ward, Charles H. Mitch
  • Process for preparing bis-indolyl macrocycles
    Patent number: 5821365
    Abstract: This invention provides novel bis-indolemaleimide macrocycle derivatives of the formula: ##STR1## wherein R.sub.1, R.sub.2, X, W, and Y are as defined in the specification. The invention further provides the preparation, pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.
    Type: Grant
    Filed: November 14, 1997
    Date of Patent: October 13, 1998
    Assignee: Eli Lilly and Company
    Inventors: Michael R. Jirousek, John H. McDonald, III, Christopher J. Rito
  • Heterocyclic compounds and their preparation and use
    Patent number: 5821370
    Abstract: The present invention relates to therapeutically active azacyclic or azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 13, 1998
    Assignee: Eli Lilly and Company
    Inventors: Charles A. Alt, Leander Merritt, Gary A. Rhodes, Roger L. Robey, Eldon E. Van Meter, John S. Ward
  • Glycosyltransferase gene gtfb from Amycolatopsis orientalis
    Patent number: 5821100
    Abstract: The invention provides isolated nucleic acid compounds encoding the glycosyltransferase protein GtfB of Amycolatopsis orientalis. Also provided are vectors carrying the gtfB gene, transformed heterologous host cells for expressing the GtfB protein, and methods for producing glycopeptide compounds using the cloned gtfB gene.
    Type: Grant
    Filed: September 5, 1997
    Date of Patent: October 13, 1998
    Assignee: Eli Lilly and Company
    Inventors: Richard H. Baltz, Patricia J. Solenberg
  • Anti-viral compounds
    Patent number: 5821242
    Abstract: The present application provides a series of benzimidazole compounds which inhibit the growth of picornaviruses, such as rhinoviruses, enteroviruses, polioviruses, coxsackieviruses of the A and B groups, echo virus and Mengo virus and flaviviruses such as hepatitis C and bovine diarrheal virus.
    Type: Grant
    Filed: June 4, 1997
    Date of Patent: October 13, 1998
    Assignee: Eli Lilly and Company
    Inventors: Joseph Matthew Colacino, Beverly Ann Heinz, Louis Nickolaus Jungheim, Shawn Christopher Miller, Wayne Alfred Spitzer, Joseph Chiou-chung Tang, Mark Joseph Tebbe, Frantz Victor
  • Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
    Patent number: 5821357
    Abstract: A stereoselective glycosylation process for preparing beta-anomer enriched 2'-deoxy-2',2'-difluoropurine and triazole nucleosides and 2'-deoxy-2'-fluoropurine and triazole nucleosides which involves reacting an alpha-anomer enriched 2-deoxy-2,2-difluorocarbohydrate or 2-deoxy-2-fluorocarbohydrate with at least a molar equivalent of a nucleobase derivative in a low freezing inert solvent.
    Type: Grant
    Filed: April 7, 1993
    Date of Patent: October 13, 1998
    Assignee: Eli Lilly and Company
    Inventors: Ta-Sen Chou, Charles D. Jones
  • Glycosyltransferase gene GtfA from Amycolatopsis orientalis
    Patent number: 5821099
    Abstract: The invention provides isolated nucleic acid compounds encoding the glycosyltransferase protein GtfA of Amycolatopsis orientalis. Also provided are vectors carrying the gtfA gene, transformed heterologous host cells for expressing the GtfA protein, and methods for producing glycopeptide compounds using the cloned gtfA gene.
    Type: Grant
    Filed: September 5, 1997
    Date of Patent: October 13, 1998
    Assignee: Eli Lilly and Company
    Inventors: Richard H. Baltz, Patricia J. Solenberg
  • Biosynthetic gene murg from streptococcus pneumoniae
    Patent number: 5821335
    Abstract: The invention provides isolated nucleic acid compounds encoding the stem peptide biosynthetic gene murG of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the MurG enzyme product and a method for identifying compounds that inhibit stem peptide biosynthesis.
    Type: Grant
    Filed: November 19, 1996
    Date of Patent: October 13, 1998
    Assignee: Eli Lilly and Company
    Inventors: Jo Ann Hoskins, Paul Luther Skatrud, Robert Brown Peery
  • Methods of treatment using a thieno-benzodiazepine
    Patent number: 5817655
    Abstract: 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno -?2,3-b!?1,5!benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system.
    Type: Grant
    Filed: November 13, 1996
    Date of Patent: October 6, 1998
    Assignees: Eli Lilly and Company, Eli Lilly and Company Limited
    Inventors: Jiban Kumar Chakrabarti, Terrence Micharl Hotten, David Edward Tupper
  • Indazolecarboxamides
    Patent number: 5817676
    Abstract: Indazolecarboxamides are used as antagonists and partial agonists for the serotonin receptor 5-HT.sub.4 and provide therapeutic methods for treatment of disorders caused by or affected by dysfunction of the 5-HT.sub.4 receptor.
    Type: Grant
    Filed: January 10, 1997
    Date of Patent: October 6, 1998
    Assignee: Eli Lilly and Company
    Inventors: John T. Catlow, Marlene L. Cohen, Michael O. Martinelli, John M. Schaus, Steven Swanson, Dennis C. Thompson, Thomas M. Wilson
  • 5-HT.sub.1F agonists
    Patent number: 5817671
    Abstract: This invention provides 5-HT.sub.1F agonists of Formula I: ##STR1## where A--B, X, and R are as defined in the specification. The invention also encompasses pharmaceutical formulations employing compounds of Formula I as well as methods of treating conditions associated with 5-HT.sub.1F activation employing these compounds or compositions. The invention also provides intermediates useful for the preparation of the compounds of Formula I.
    Type: Grant
    Filed: November 14, 1997
    Date of Patent: October 6, 1998
    Assignee: Eli Lilly and Company
    Inventors: Sandra Ann Filla, Kirk W. Johnson, Lee A. Phebus, John Mehnert Schaus
  • Method for treating substance abuse withdrawal
    Patent number: 5816260
    Abstract: This invention provides a method for treating a condition resulting from the cessation or withdrawal of tobacco or nicotine, opioids, ethanol or combinations thereof comprising administering an effective amount of 4-chloro-5-(imidazoline-2-y(amino)-6-methoxy-2-methylpyrimidine.
    Type: Grant
    Filed: December 3, 1997
    Date of Patent: October 6, 1998
    Assignee: Eli Lilly and Company
    Inventors: Mary J. Kallman, Kurt Rasmussen
  • Psychoactive substance disorders
    Patent number: 5817657
    Abstract: 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-?2,3-b!?1,5!benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders relating to the use of psychoactive substances.
    Type: Grant
    Filed: November 13, 1996
    Date of Patent: October 6, 1998
    Assignees: Eli Lilly and Company, Eli Lilly and Company Limited
    Inventors: Charles M. Beasley, Jr., Jiban Kumar Chakrabarti, Terrence Michael Hotten, David Edward Tupper
  • Leukotriene antagonists for use in the treatment or inhibition of cerebral focal stroke
    Patent number: 5817684
    Abstract: This invention provides methods for the treatment or prevention of cerebral focal ischemia which comprises administering to a mammal in need thereof an effective amount of a compound having activity as a leukotriene B.sub.4 antagonist.
    Type: Grant
    Filed: December 2, 1997
    Date of Patent: October 6, 1998
    Assignee: Eli Lilly and Company
    Inventors: Jerome H. Fleisch, William T. Jackson, Jason S. Sawyer
  • Mental disorders
    Patent number: 5817656
    Abstract: 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-?2,3-b!?1,5!benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of mental disorders.
    Type: Grant
    Filed: November 13, 1996
    Date of Patent: October 6, 1998
    Assignees: Eli Lilly and Company, Eli Lilly and Company Limited
    Inventors: Charles M. Beasley, Jr., Jiban Kumar Chakrabarti, Terrence Michael Hotten, David Edward Tupper
  • Fusion proteins comprising cell cycle regulatory proteins
    Patent number: 5814503
    Abstract: The present invention provides novel fusion proteins comprising cyclins and CDKs. A preferred embodiment of the invention provides fusion proteins comprising human cyclin D1 and human CDK4. The fusion proteins of the invention optionally contain modifications, which facilitate their purification. Addition of histidine residues to selected constructs allows purification via immobilized metal affinity chromatography. Antigenic determinants allowing monoclonal antibody-based affinity chromatography purification are provided in selected embodiments of the invention. Protease cleavage sites are incorporated in selected constructs to allow cleavage of the regions incorporated in the cyclin-CDK fusion proteins for purification. Additional modifications which facilitate purification include strepavadin binding domains and antigenic determinants for antibody affinity chromatography.
    Type: Grant
    Filed: December 19, 1996
    Date of Patent: September 29, 1998
    Assignee: Eli Lilly and Company
    Inventors: Steven Kovacevic, Keith A. Otto, Ramachandra N. Rao
  • Pharmaceutical method using 6-substituted-1, 2, 3, 4-tetrahydro-9H-carbazoles and 7-substituted-10H -cyclohepta (7, 6-B) indoles
    Patent number: 5814653
    Abstract: This invention provides novel 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta?7,6-b!indoles. These compounds are 5-HT.sub.1F agonists which are useful for the treatment of migraine and associated disorders.
    Type: Grant
    Filed: December 17, 1997
    Date of Patent: September 29, 1998
    Assignee: Eli Lilly and Company
    Inventors: Michael Edward Flaugh, Anton Daniel Kiefer, Jr., Clint Duane Walker, Yao-Chang Xu
  • Inhibitors of amyloid beta-protein production
    Patent number: 5814646
    Abstract: A method of protecting a warm-blooded mammal from the progression of Alzheimer's disease, which comprises administering an effective amount of a compound of general formula. ##STR1## in which: R.sup.1 represents an optionally substituted aromatic or heteroaromatic group;L.sup.1 and L.sup.2 each independently represents a bond or an unbranched (1-4C) alkylene group, which alkylene group may optionally bear a (1-4C) alkyl, phenyl or phenyl (1-2C) alkyl substituent;one of Y.sup.1 and Y.sup.2 represents NR.sup.3 and the other represents O, S or NR.sup.3, in which R.sup.3 represent hydrogen, hydroxyl, (1-4C) alkoxy, (1-4C) alkyl or di (1-4C) alkylamino;Z represents O or S; andR.sup.2 represents (3-8C) cycloalkyl, heterocyclyl, and optionally substituted aromatic or heteroaromatic group, or together with L.sup.2, (1-10C) alkyl;or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 2, 1995
    Date of Patent: September 29, 1998
    Assignee: Eli Lilly and Company
    Inventors: Lawrence J. Heinz, Jill A. Panetta, Michael L. Phillips, Jon K. Reel, John K. Shadle, Richard L. Simon, Celia A. Whitesitt
  • Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
    Patent number: 5811120
    Abstract: This invention provides solid orally administerable pharmaceutical formulations comprising raloxifene hydrochloride, a surfactant being sorbitan fatty acid ester or a polyoxyethylene sorbitan fatty acid ester, polyvinylpyrrolidone, and a water soluble diluent which is polyol or sugar.
    Type: Grant
    Filed: March 26, 1997
    Date of Patent: September 22, 1998
    Assignee: Eli Lilly and Company
    Inventors: Lowell L. Gibson, Kerry J. Hartauer, Julian L. Stowers, Stephanie A. Sweetana, Arvind L. Thakkar
  • Syringe alignment device
    Patent number: D399313
    Type: Grant
    Filed: March 26, 1996
    Date of Patent: October 6, 1998
    Assignee: Eli Lilly and Company
    Inventors: Roland Joseph Bydlon, Javan Eronmy Collins, William Harold Morrison, Jr., Bradley Ray Newman